TapewireFind a company

person · Reporting owner

Swain Judith L

Disclosed activity across 2 companies

Tapewire entity
41455
SEC CIK
0001413573

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970DirectorJune 03, 2026June 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

LEXICON PHARMACEUTICALS, INC.

Report date June 03, 2026 · Filed June 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect174,486 Reported balance After 2026-06-03 transaction · row 1
1 source row

Row 1 · 2026-06-03 · Exercise / conversion · Acquired 89,312 · Balance 174,486

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct0 Reported balance After 2026-06-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-06-03 · Exercise / conversion · Disposed 89,312 · Balance 0

F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2: Each restricted stock unit represents a contingent right to receive one share of common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2: Each restricted stock unit represents a contingent right to receive one share of common stock.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Prometheus Biosciences, Inc.

Report date June 16, 2023 · Filed June 16, 2023

Section 16 reporting ended · disclosed 2023-06-16. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2023-06-16 transaction · row 1
1 source row

Row 1 · 2023-06-16 · Disposition to issuer · Disposed 2,071 · Balance 0

F1: Reflects restricted stock units.

F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.70 · Expires 2031-02-04Direct0 Reported balance After 2023-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2023-06-16 · Disposition to issuer · Disposed 30,000 · Balance 0

F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.02 · Expires 2032-05-18Direct0 Reported balance After 2023-06-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2023-06-16 · Disposition to issuer · Disposed 20,500 · Balance 0

F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects restricted stock units.

F2: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 03, 2026 Filed Jun 4, 2026 20:14 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionRestricted Stock Units · Derivative 89,312 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001062822-26-000108 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 89,312 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
June 03, 2026 Filed Jun 4, 2026 20:14 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionCommon Stock 89,312 $0.00 $0.00
Disclosure

SEC source: 0001062822-26-000108 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,486

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 01, 2026 Filed May 4, 2026 20:27 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 43,478 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001062822-26-000080 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,478

Underlying: Common Stock · 43,478 shares

Expires 2036-05-01

F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Read SEC document
May 01, 2026 Filed May 4, 2026 20:27 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantRestricted Stock Units · Derivative 35,714 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001062822-26-000080 · form4.xml · derivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,714

Underlying: Common Stock · 35,714 shares

Expires not disclosed

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
June 03, 2025 Filed Jun 3, 2025 20:25 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantRestricted Stock Units · Derivative 89,312 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-25-016480 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,312

Underlying: Common Stock · 89,312 shares

Expires not disclosed

F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
June 03, 2025 Filed Jun 3, 2025 20:25 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 103,806 $0.00 Strike: $0.62 $0.00
Disclosure

SEC source: 0001127602-25-016480 · form4.xml · derivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,806

Underlying: Common Stock · 103,806 shares

Expires 2035-06-03

F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Read SEC document
May 13, 2025 Filed May 13, 2025 21:52 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionRestricted Stock Units · Derivative 36,810 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-25-014146 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 36,810 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
May 13, 2025 Filed May 13, 2025 21:52 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionCommon Stock 36,810 $0.00 $0.00
Disclosure

SEC source: 0001127602-25-014146 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,174

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 13, 2024 Filed May 13, 2024 20:05 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantRestricted Stock Units · Derivative 36,810 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-24-015084 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,810

Underlying: Common Stock · 36,810 shares

Expires not disclosed

F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
May 13, 2024 Filed May 13, 2024 20:05 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 44,906 $0.00 Strike: $1.79 $0.00
Disclosure

SEC source: 0001127602-24-015084 · form4.xml · derivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,906

Underlying: Common Stock · 44,906 shares

Expires 2034-05-13

F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Read SEC document
April 28, 2024 Filed Apr 29, 2024 20:21 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionRestricted Stock Units · Derivative 8,032 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-24-013558 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,032 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 28, 2024 Filed Apr 29, 2024 20:21 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionCommon Stock 8,032 $0.00 $0.00
Disclosure

SEC source: 0001127602-24-013558 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,364

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC Prometheus Biosciences, Inc. RXDX · Entity 112175 Disposition to issuerStock Option (right to buy) · Derivative 20,500 Not disclosed Strike: $29.02 Not disclosed
Disclosure

SEC source: 0000899243-23-015756 · doc4.xml · derivative · entry 3

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,500 shares

Expires 2032-05-18

F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC Prometheus Biosciences, Inc. RXDX · Entity 112175 Disposition to issuerStock Option (right to buy) · Derivative 30,000 Not disclosed Strike: $6.70 Not disclosed
Disclosure

SEC source: 0000899243-23-015756 · doc4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2031-02-04

F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3 · derivative.exercise_date: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Read SEC document
June 16, 2023 Filed Jun 16, 2023 20:00 UTC Prometheus Biosciences, Inc. RXDX · Entity 112175 Disposition to issuerCommon Stock 2,071 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-23-015756 · doc4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Reflects restricted stock units.

F2 · price: Pursuant to the Agreement and Plan of Merger, dated April 15, 2023, by and among the Issuer, Merck & Co., Inc. ("Merck") and Splash Merger Sub, Inc., the Issuer became a wholly owned subsidiary of Merck upon consummation of the merger (the "Effective Time"). At the Effective Time, (a) each of the Issuer's outstanding shares of common stock was cancelled and automatically converted into the right to receive $200 in cash (the "Merger Consideration"), without interest,... (Continued in Footnote 3)

F3 · price: (Continued from Footnote 2) ...(b) each of the Issuer's outstanding restricted stock units ("RSUs") was automatically cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of the Issuer's common stock underlying such RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration, without interest and (c) each of the Issuer's outstanding unexercised stock options, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the number of shares of the Issuer's common stock underlying such option immediately prior to the Effective Time multiplied by (ii) the amount, if any, by which the Merger Consideration exceeded the exercise price per share of such option.

Read SEC document
May 21, 2023 Filed May 22, 2023 20:07 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionRestricted Stock Units · Derivative 9,302 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-23-016439 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,302 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
May 21, 2023 Filed May 22, 2023 20:07 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionCommon Stock 9,302 $0.00 $0.00
Disclosure

SEC source: 0001127602-23-016439 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,332

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 19, 2023 Filed May 19, 2023 21:45 UTC Prometheus Biosciences, Inc. RXDX · Entity 112175 GrantCommon Stock 2,071 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-031191 · doc4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,071

F1 · kind: Award of restricted stock units ("RSUs") granted under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The RSUs shall vest in full upon the earlier to occur of (i) the first anniversary of the date of grant, (ii) the Issuer's next occurring annual meeting of stockholders, or (iii) a Change of Control (as defined in the 2021 Plan), subject to the Reporting Person's continued service with the Issuer on such vesting date.

Read SEC document
April 28, 2023 Filed Apr 28, 2023 20:30 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 12,658 $0.00 Strike: $2.36 $0.00
Disclosure

SEC source: 0001127602-23-013789 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,658

Underlying: Common Stock · 12,658 shares

Expires 2033-04-28

F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Read SEC document
April 28, 2023 Filed Apr 28, 2023 20:30 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantRestricted Stock Units · Derivative 8,032 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-23-013789 · form4.xml · derivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,032

Underlying: Common Stock · 8,032 shares

Expires not disclosed

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
May 21, 2022 Filed May 23, 2022 20:18 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantRestricted Stock Units · Derivative 9,302 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-22-015379 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,302

Underlying: Common Stock · 9,302 shares

Expires not disclosed

F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
May 21, 2022 Filed May 23, 2022 20:18 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 14,402 $0.00 Strike: $1.77 $0.00
Disclosure

SEC source: 0001127602-22-015379 · form4.xml · derivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,402

Underlying: Common Stock · 14,402 shares

Expires 2032-05-21

F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Read SEC document
May 19, 2022 Filed May 20, 2022 23:28 UTC Prometheus Biosciences, Inc. RXDX · Entity 112175 GrantStock Option (Right to Buy) · Derivative 20,500 $0.00 Strike: $29.02 $0.00
Disclosure

SEC source: 0001209191-22-031177 · doc4.xml · derivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,500

Underlying: Common Stock · 20,500 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to the option will vest in full upon the earlier to occur of (i) the first anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Read SEC document
April 30, 2022 Filed May 2, 2022 20:22 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionRestricted Stock Units · Derivative 4,024 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-22-012835 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,024 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 30, 2022 Filed May 2, 2022 20:22 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionCommon Stock 4,024 $0.00 $0.00
Disclosure

SEC source: 0001127602-22-012835 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,030

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 30, 2021 Filed May 3, 2021 21:06 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 6,475 $0.00 Strike: $5.04 $0.00
Disclosure

SEC source: 0001127602-21-014971 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,475

Underlying: Common Stock · 6,475 shares

Expires 2031-04-30

F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Read SEC document
April 30, 2021 Filed May 3, 2021 21:06 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantRestricted Stock Units · Derivative 4,024 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-21-014971 · form4.xml · derivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,024

Underlying: Common Stock · 4,024 shares

Expires not disclosed

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 24, 2021 Filed Apr 27, 2021 20:51 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionRestricted Stock Units · Derivative 10,638 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-21-014524 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,638 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 24, 2021 Filed Apr 27, 2021 20:51 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionCommon Stock 10,638 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-014524 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,006

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 26, 2020 Filed Apr 27, 2020 20:49 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionRestricted Stock Units · Derivative 3,466 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-014572 · form4.xml · derivative · entry 4

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,466 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 26, 2020 Filed Apr 27, 2020 20:49 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 Exercise / conversionCommon Stock 3,466 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-014572 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,368

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 24, 2020 Filed Apr 27, 2020 20:49 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantRestricted Stock Units · Derivative 10,638 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-20-014572 · form4.xml · derivative · entry 3

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,638

Underlying: Common Stock · 10,638 shares

Expires not disclosed

F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 24, 2020 Filed Apr 27, 2020 20:49 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 18,115 $0.00 Strike: $1.86 $0.00
Disclosure

SEC source: 0001127602-20-014572 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,115

Underlying: Common Stock · 18,115 shares

Expires 2030-04-24

F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Read SEC document
April 26, 2019 Filed Apr 29, 2019 21:03 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantRestricted Stock Units · Derivative 3,466 $0.00 $0.00
Disclosure

SEC source: 0001127602-19-016492 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,466

Underlying: Common Stock · 3,466 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.

F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock.

Read SEC document
April 26, 2019 Filed Apr 29, 2019 21:03 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 6,519 $0.00 Strike: $5.67 $0.00
Disclosure

SEC source: 0001127602-19-016492 · form4.xml · derivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,519

Underlying: Common Stock · 6,519 shares

Expires 2029-04-26

F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date.

Read SEC document
April 27, 2018 Filed Apr 27, 2018 21:42 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 2,857 $0.00 Strike: $7.80 $0.00
Disclosure

SEC source: 0001127602-18-015457 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,857

Underlying: Common Stock · 2,857 shares

Expires 2028-04-27

F1 · derivative.exercise_date: Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant.

Read SEC document
April 27, 2018 Filed Apr 27, 2018 21:42 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantCommon Stock 2,564 $0.00 $0.00
Disclosure

SEC source: 0001127602-18-015457 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,902

Read SEC document
April 28, 2017 Filed May 1, 2017 20:54 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantStock Option (Right to Buy) · Derivative 2,857 $0.00 Strike: $15.61 $0.00
Disclosure

SEC source: 0001127602-17-016072 · form4.xml · derivative · entry 2

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,857

Underlying: Common Stock · 2,857 shares

Expires 2027-04-28

F1 · derivative.exercise_date: Option vests with respect to 1/12th of the shares subject to the option for each month of service following the date of grant.

Read SEC document
April 28, 2017 Filed May 1, 2017 20:54 UTC LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 GrantCommon Stock 1,281 $0.00 $0.00
Disclosure

SEC source: 0001127602-17-016072 · form4.xml · nonDerivative · entry 1

Swain Judith L · CIK 0001413573 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,338

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.